( January 16, 2026, 3:48 PM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 16 granted a bioequivalent pharmaceutical maker’s petition for a writ of certiorari, agreeing to consider its challenge to the Federal Circuit U.S. Court of Appeals’ finding that the petitioner’s “skinny label” generic version of a prescription cardiovascular medication constituted reverse infringement....